ABCC6 and chronic myelogenous leukemia, BCR-ABL1 positive: The concomitant administration of ABCC6 inhibitors and tyrosine kinase inhibitors has been suggested as a therapeutic option for the treatment of chronic myeloid leukemia [12], and it could certainly be interesting to evaluate its potential on hepatoma cell cultures.